Mutation Analysis of the ADAR1 Gene in Dyschromatosis Symmetrica Hereditaria and Genetic Differentiation from both Dyschromatosis Universalis Hereditaria and Acropigmentatio Reticularis  by Suzuki, Noriyuki et al.
Mutation Analysis of the ADAR1 Gene in Dyschromatosis
Symmetrica Hereditaria and Genetic Differentiation from both
Dyschromatosis Universalis Hereditaria and Acropigmentatio
Reticularis
Noriyuki Suzuki, Tamio Suzuki, Katsuhiko Inagaki, Shiro Ito, Michihiro Kono, Kazuyoshi Fukai,w
Hiromichi Takama,z Kenji Sato,y Osamu Ishikawa,z Masatoshi Abe,z Hiroshi Shimizu,# Masaaki Kawai,
Tatsuya Horikawa,ww Kunihiro Yoshida,zz Kazuhiko Matsumoto,yy Tadashi Terui,zz Kaoru Tsujioka,##
and Yasushi Tomita
Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Japan; wDepartment of Dermatology, Osaka City University Graduate
School of Medicine, Osaka, Japan; zTakama Dermatology Clinic, Kasugai, Aichi, Japan; yDepartment of Dermatology, Kinki Central Hospital, Itami, Japan;
zDepartment of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan; #Department of Dermatology, Hokkaido University Graduate
School of Medicine, Sapporo, Japan; Department of Dermatology, Juntendo University Urayasu Hospital, Urayasu, Japan; wwDepartment of Dermatology, Kobe
University Graduate School of Medicine, Kobe, Japan; zzDivision of Clinical and Molecular Genetics, Shinshu University Hospital, Matsumoto, Japan; yyClinical
Trial Research Center, Shinshu University Hospital, Matsumoto, Japan; zzDepartment of Dermatology, Tohoku University Graduate School of Medicine, Sendai,
Japan; ##Department of Dermatology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan
Dyschromatosis symmetrica hereditaria (DSH) (also called ‘‘reticulate acropigmentation of Dohi’’) is a pigmentary
genodermatosis of autosomal dominant inheritance. We have clariﬁed for the ﬁrst time four pathological mutations
of the double-stranded RNA-specific adenosine deaminase gene (ADAR1 or DSRAD) in four DSH pedigrees. In this
paper, we report 16 novel mutations containing six missense substitutions (p.V906F, p.K1003R, p.G1007R,
p.C1036S, p.S1064F, p.R1078C), two splice site mutations (IVS2þ 2T4G, IVS8þ 2T4A), six frameshift mutations
(p.H216fs, p.K433fs, p.G507fs, p.P727fs, p.V955fs, p.K1201fs), and two nonsense mutations (p.R426X, p.Q600X)
found in Japanese patients with DSH. We did not establish any clear correlation between the clinical phenotypes
and the genotypes of ADAR1 gene mutations in our examination of 16 cases plus four pedigrees. None of the
different mutations identiﬁed in our studies of 20 cases suggested any founder effect. Furthermore, we did not
identify any mutations in the ADAR1 gene of three patients with dyschromatosis universalis hereditaria or three
patients with acropigmentatio reticularis, indicating that the two diseases are completely different from DSH,
although they have sometimes been suggested to be phenotypical variations of DSH.
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Dyschromatosis symmetrica hereditaria (DSH [MIM127400])
(also called ‘‘reticulate acropigmentation of Dohi’’) is an au-
tosomal dominant disease characterized by a mixture of
hyperpigmented and hypopigmented macules distributed
on the dorsal aspects of the extremities and freckle-like
macules on the face (Toyama, 1910, 1929) (Fig 1A and B).
DSH has been reported mainly in Japan, although a few
cases were described among Koreans, Indians, Chinese,
Europeans, and South Americans (Oyama et al, 1999). Re-
cently, 17 DSH families including 136 cases in China were
reported (He et al, 2004), indicating that this disorder might
be distributed mainly in East Asia. The difference in the fre-
quency of this disorder between East Asia and other regions
may be related to genetic background and/or environment,
e.g., the amount of UV exposure. From the results of linkage
analysis and a genome-wide scan, we have for the first time
clarified that a heterozygous mutation of the RNA-specific
adenosine deaminase gene (ADAR1, DSRAD) causes DSH,
and have also reported four heterozygous mutations of
p.R474X, p.L923P, p.K952X, and p.F1165S in the ADAR1
gene responsible for DSH in Japanese families (Miyamura
et al, 2003). Subsequently, two groups reported two and
eight novel mutations in the ADAR1 gene in Chinese pa-
tients with DSH, respectively (Li et al, 2004; Liu et al, 2004;
Zhang et al, 2004), which confirmed that the ADAR1 gene is
responsible for DSH not only in Japanese but also in an-
other ethnic groups.
ADAR1 was identified as the first enzyme that converts
adenosine to inosine in double-stranded RNA (Bass and
Weintraub, 1988). Inosine acts as guanosine during trans-
lation and reverse-transcription. It appears to be the most
widespread type of nuclear pre-mRNA editing in higher
eukaryotes. RNA editing reactions occur in many organisms
and operate by different molecular mechanisms. In some
Abbreviations: ADAR, adenosine deaminase acting on RNA; AR,
acropigmentatio reticularis; DSH, dyschromatosis symmetrica her-
editaria; DSRAD, double-stranded RNA-specific adenosine dea-
minase; DUH, dyschromatosis universalis hereditaria; SSCP/HD,
single-strand conformation polymorphism/heteroduplex
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substrates, the editing occurs at specific sites to produce
codon changes within open reading frames, whereas in
others an alternative splice acceptor site is created, or
modulation of mRNA stability or transport is changed by
editing pre-mRNA (Maas et al, 2003). Loss of those func-
tions might cause the phenotypes of DSH, although the
mechanisms still remain unknown.
There are two diseases showing phenotypes so similar to
DSH that they are sometimes difficult to differentiate from
DSH. One of them is dyschromatosis universalis hereditaria
(DUH [MIM127500]), initially described by Ichikawa and Hi-
raga (1933). In DUH, mixtures of hyperpigmented and hypo-
pigmented macules occur all over the body (Fig 1C). By the
localization of the skin lesions, the disease can be discrim-
inated from DSH. And DUH has been thought to be distinct
from DSH because they have not been found together in the
same pedigree. We previously suggested (Miyamura et al,
2003) that DUH might have been the diagnosis in the two
families in which Xing et al (2003) found linkage
to 6q24.2–q25.2. The other disease is acropigmentatio re-
ticularis (AR) (Kitamura et al, 1953), also called ‘‘reticulate
acropigmentation of Kitamura’’ (Griffiths, 1976), which is also
an autosomal dominant disease characterized by reticulate,
hyperpigmented macules distributed on the dorsal aspects
of the hand and feet, ‘‘pits’’ on the palms, and the absence
of hypopigmented macules (Fig 1D and E). It is controversial
whether AR is a variant of DSH. So far there has been no
report on the chromosomal location or etiology of AR.
In this paper, we report 16 novel mutations in Japanese
patients with DSH; these mutations help to define a func-
Figure 1
Clinical phenotypes of dyschromatosis symmetrica hereditaria (DSH), dyschromatosis universalis hereditaria (DUH), and acropigmentatio
reticularis (AR). (A) Patient 3 with DSH, (B) patient 8 with DSH. The mixtures of hyper- and hypopigmented macules on the dorsal aspects of hands
were various. The phenotype in patient 3 was faint and less severe than that in patient 8. (C) DUH. Mixtures of hyper- and hypopigmented macules
occur all over the body. (D), (E) AR. Hyperpigmented macules distributed on the dorsal aspects of the hands and feet with no hypopigmented ones.
‘‘Pits’’ on the palms (arrows) were observed.
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tionally important region in the deaminase domain. We also
report that none of the three patients with DUH or the three
patients with AR had any mutations in the ADAR1 gene,
supporting the notion that DSH is a distinct disease from
DUH or AR. This is a report showing molecular evidence of
the differences between DSH and DUH as well as AR.
Results and Discussion
Mutations of the ADAR1 gene in patients with
DSH PCR-single-strand conformation polymorphism/he-
teroduplex (SSCP/HD) screening and direct sequencing of
the 16 patients with DSH revealed 16 novel mutations of the
ADAR1 gene (Table I). The 16 novel mutations included
six missense substitutions (p.V906F, p.K1003R, p.G1007R,
p.C1036S, p.S1064F, p.R1078C), two splice site muta-
tions (IVS2þ2T4G, IVS8þ 2T4A), six frameshift muta-
tions (p.H216fs, p.K433fs, p.G507fs, p.P727fs, p.V955fs,
p.K1201fs), and two nonsense mutations (p.R426X,
p.Q600X). We examined the frequency of the six missense
and the two splice site mutant alleles in the ADAR1 gene of
114 unrelated normally pigmented Japanese subjects (228
alleles), and no mutant allele was detected. This suggested
that those 8 alleles were very rare in the normal Japanese
population and could be defined statistically as pathological
alleles. Furthermore, in the case of a splice site mutation,
IVS8þ 2T4A, we confirmed an aberrant splice product with
RT-PCR and DNA direct sequence analysis. The result re-
vealed that exon 8 was spliced to exon 9 with the presence
of the first 80 nucleotides from intron 8, resulting in a
frameshift and a truncated protein with an additional 2-
amino-acid peptide. In another splice site mutation,
IVS2þ 2T4G, we predicted that the T4G change at the
second base of IVS2 might cause a similar aberrant splic-
ing. We could not, however, obtain experimental evidence
because the patient did not agree to provide an additional
blood sample for the RT-PCR work. All of the six novel
missense mutations identified in this study and another five
missense mutations described previously (Miyamura et al,
2003; Li et al, 2004; Liu et al, 2004; Zhang et al, 2004) were
Table I. Mutations of the ADAR1 gene in this study
Patient Disease Incidence
Affected
individuals
Unaffected
individuals
Nucleotide
changea
Amino acid
change Exon Mutation type
1 DSH Familial 3 1 c.645–646insCC p.H216fsX261 EX2 Frameshift
2 DSH Familial 4 9 c.1276A4T p.R426X EX2 Nonsense
c.1826T4C p.F609S EX4 Missense
3 DSH Familial 5 11 c.1296–1297insTG p.K433fsX433 EX2 Frameshift
4 DSH Familial 7 5 c.1521delG p.G507fsX509 EX2 Frameshift
5 DSH Familial 6 9 IVS2þ 2T4G Unknown IVS2 Splice mutation
6 DSH Familial 5 2 c.1798C4T p.Q600X EX4 Nonsense
7 DSH Familial 4 15 c.2180delC p.P727fsX792 EX6 Frameshift
8 DSH Familial 7 13 IVS8þ 2T4A p.G890fsX892 IVS8 Splice mutation
9 DSH Sporadic — — c.2716G4T p.V906F EX9 Missense
10 DSH Familial 2 6 c.2865–2866delGT p.V955fsX972 EX10 Frameshift
11 DSH Familial 7 5 c.3008A4G p.K1003R EX11 Missense
12 DSH Familial 2 10 c.3019G4A p.G1007R EX11 Missense
13 DSH Sporadic — — c.3107G4C p.C1036S EX12 Missense
c.1752–1754delATC p.S585del EX3 Frameshift
14 DSH Familial 3 10 c.3191C4T p.S1064F EX12 Missense
15 DSH Familial 5 3 c.3232C4T p.R1078C EX13 Missense
16 DSH Familial 8 9 c.3603delA p.K1201fsX1203 EX15 Frameshift
17 DUH Familial 4 6 None None
18 DUH Sporadic — — None None
19 DUH Sporadic — — None None
20 AR Familial 2 1 None None
21 AR Familial 4 4 None None
22 AR Sporadic — — None None
aGenBank Accession No. NM_001111. Position 1 is A of the translation initiation codon.
DSH, dyschromatosis symmetrica hereditica.
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located at amino-acid residues conserved among the
zebrafish, frog, chicken, mouse, and human within the
deaminase domain of the ADAR1 protein (Fig 2). These re-
sults suggested that the mutations play an important role in
the confirmation of the catalytic site of the enzyme and likely
influence the deaminase activity.
Patient 2 turned out to have two mutations, p.R426X and
p.F609S (Table I). We examined the frequency of these two
mutations among 101 of the normally pigmented Japanese
subjects (202 alleles), and neither mutation was detected.
Further analysis of his father with DSH showed that he also
had both mutations, indicating that the two mutations must
be certainly on the same allele derived from him, but not on
two heterozygous alleles. Therefore, the p.F609S mutation
might not give any influence in this patient because of the
existence of the previous p.R426X mutation, which would
lead to premature translation resulting in a truncated protein
with no functional activity. And this would not be contra-
dictory to a report that homozygosity for the Adar1 null
mutation would cause embryonic lethality in mice (Wang
et al, 2004).
Identiﬁcation of polymorphisms We identified six novel
polymorphisms in the exonic or the nearby intronic se-
quences in the ADAR1 gene, and the frequencies were de-
termined for 16 patients with DSH and 113 unrelated normal
Japanese subjects (Table II). Two of the exonic polymorph-
isms resulted in amino-acid changes (p.K384R, p.Y587C),
one resulted in an in-frame mutation (p.S585del), whereas
the remaining ones were silent. A three-base deletion (ATC)
at c.1752–1754, which was an in-frame mutation resulting in
a deletion of serine located outside of the deaminase do-
main, was found in one patient (patient 13) and two normally
pigmented Japanese. Patient 13 was homozygous for this
deletion and heterozygous for p.C1036S (Table II). The ami-
no-acid substitution from cystein to serine at codon 1036 is
a non-conserved change located within the deaminase do-
main, suggesting a pathological mutation. And the two nor-
mal subjects who were heterozygous for p.S585del mutant
allele had no evidence for DSH. Based on these data, we
concluded that the deletion of the serine codon 585 is a
sequence polymorphism rather than a pathogenic mutation,
although the possibility of a rare recessive allele cannot be
excluded.
The relationship between the phenotype and the mutant
genotype in the ADAR1 gene We compared the clinical
features among the patients with the mutations identified in
the 16 cases. All of the patients had a mixture of hyper- and
hypopigmented macules to various extents, which first ap-
peared in infancy or early childhood. Some patients (e.g.,
patient 8, Fig 1B) had markedly clear macules. On the other
hand, faint macules were found on the dorsal aspects of the
extremities of the other patients (e.g., patient 3, Fig 1A). We
failed, however, to find any relationship between the phe-
notypes and genotypes; even in the same family and ped-
igree among those who had the same mutation, the pattern
and the degree of the skin lesions were various. There was
no tendency that the phenotype in a patient who had a
missense mutation or a relatively long truncation peptide
might be less severe than that in a patient with an early
truncation mutation. These data indicated that the pheno-
types might be influenced not only by mutant genotypes in
the ADAR1 gene but also by other genes or, possibly, the
patient’s environment, e.g., repeated exposure to UV light
on the dorsal aspects of the hands and feet.
DUH and AR We screened mutations in the ADAR1 gene in
the three patients with DUH and three patients with AR by
both the SSCP/HD method and direct sequencing of all
their PCR products. No mutation, however, was identified
(Table I). These findings indicated that the gene causing
DUH or AR should be different from ADAR1 and that these
disorders are genetically and etiologically distinct from
DSH. And they also supported our previous suggestion that
DSH and DUH may be two distinct diseases, that is, the
Figure 2
Mutations of the ADAR1 gene found in pa-
tients with dyschromatosis symmetrica her-
editaria. The new mutations and polymorphisms
identified in this study are indicated by black and
pink arrows, respectively. Blue, green, red, and
yellow arrows indicate mutations reported pre-
viously. N, N-terminal; C, C-terminal.
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locus for DUH might link to chromosome 6q24.2–q25.2
whereas that for DSH links to chromosome 1q21.3 (Mi-
yamura et al, 2003).
Recently, Nuber et al (2004) reported in an ultrastructural
skin investigation of DUH patients that DUH might not be a
disorder of the melanocyte number, but rather that of the
melanosome synthesis rate. This is intriguing in view of re-
ports describing that the pigment anomaly in DSH might be
due to the small number of melanocytes (Hata and Yokomi,
1985), indicating that the two diseases might be caused
by quite different mechanism(s) in spite of the similarity in
phenotypes.
AR had sometimes been proposed to be a variant of
DSH. Hyperpigmented macules, which are similar to those
of DSH, distribute on the dorsal aspects of the hands and
feet. The difference in clinical features from DSH is the ab-
sence of hypopigmented macules (Fig 1D), which are
always found in DSH. ‘‘Pits’’ on the palms (arrows) are
observed in AR and enable one to differentiate between
DSH and AR (Fig 1E). Our present data indicated that AR is
an entirely different disease from DSH.
ADAR1 protein is composed of 1226 amino acid res-
idues, with a calculated molecular mass of 139 kDa
(O’Connell et al, 1995). It catalyzes the deamination of
adenosine to inosine in double-stranded RNA substrates
(Bass and Weintraub, 1988; Wagner et al, 1989), which re-
sults in the creation of alternative splicing sites (Rueter et al,
1999) or alternations of codon and thus leads to functional
changes in proteins. The ADAR1 gene is expressed ubiq-
uitously (Kim et al, 1994), but a few known target genes for
ADAR1 are expressed in specific tissues, e.g., ionotropic
glutamate receptor (Higuchi et al, 1993; Lomeli et al, 1994)
and the serotonin receptor 2C subtype in the brain (Burns
et al, 1997), and hepatitis delta virus antigen in the liver
(Polson et al, 1996). And it was also reported that the
ADAR1 expression was increased in the spleen, thymus,
and peripheral lymphocytes of endotoxin-treated mice
(Yang et al, 2003). The target genes and the induction of
the enzyme in lymphocytes, however, are unlikely to be in-
volved in the pathogenesis of DSH. Wang et al recently re-
ported that homozygosity for the Adar1 knockout in mice
caused embryonic lethality, indicating that Adar1 was es-
sential for life. And they further observed that fibroblasts
derived from Adar/ embryo were prone to apoptosis in-
duced by serum deprivation. Adarþ / heterozygous mice,
however, exhibited no obvious abnormalities such as skin
lesions (Wang et al, 2004). The absence of skin lesions in
the heterozygous mice may depend on differences between
the two splices.
The mechanism by which mutations in ADAR1 gene
cause DSH still remains unknown. We speculate two hy-
potheses as follows. The first is that, when melanoblasts
migrate from the neural crest to the skin during develop-
ment, a greater reduction in ADAR1 activity might occur
at anatomic sites distant from the neural crest. The failure
of correct RNA editing may induce the differentiation of
melanoblasts to hyperactive or hypoactive melanocytes,
which then colonize in an irregular distribution resulting in
skin lesions. The second hypothesis is that the ADAR1 ac-
tivity is required for protection against stress-induced
apoptosis as mentioned above (Wang et al, 2004). Accord-
ingly, a greater reduction in ADAR1 activity would cause
apoptosis in melanocytes at sites exposed to UV light and
would result in hypopigmented macules on the back of the
hands and the top of the feet. And secondarily, hyperpig-
mentation might occur around hypopigmented macules
completing the mixture of hypo- and hyperpigmented mac-
ules. These hypotheses were based on the idea that non-
sense-mediated RNA decay would occur and DSH might
be caused by haploinsufficiency of the ADAR1 activity, be-
cause we failed to identify a clear relationship between the
phenotypes and genotypes in this study described above.
That is, there was no phenotypical difference in terms of the
kind and site of the mutations. A dominant negative effect of
mutant ADAR1 activity, however, could also be proposed as
a mechanism as well as haploinsufficiency. Recently, ho-
modimerization was demonstrated to be essential for the
enzyme activity of the ADAR1 encoded protein (Cho et al,
2003). Both the double-stranded RNA binding motif and
deaminase domain were suggested to be required for the
Table II. Polymorphisms detected in the ADAR1 gene and its frequencies in Japanese patients with DSH and normally pigmented
Japanese subjects
Nucleotide change
Amino acid
change Exon
Allele frequency in
Japanese patients
with DSH
Normally pigmented
Japanese subjects
c.1151G4A p.R384K EX2 7/24(0.29) 10/36(0.28)
c.1410A4Ga p.P470P (silent) EX2 0/32(0.00) 1/36(0.03)
c.1752–1754delATCa p.S585del EX3 2/32(0.06) 2/226(0.01)
c.1760A4Ga p.Y587C EX3 0/32(0.00) 2/226(0.01)
IVS3þ5G4Aa None IVS3 0/32(0.00) 4/226(0.02)
IVS4-20C4Ta None IVS4 1/32(0.03) 1/36(0.03)
c.2682G4A p.V894V (silent) EX9 7/20(0.35) 64/222(0.29)
IVS11þ 9T4Ca None IVS11 0/32(0.00) 1/36(0.03)
aNovel polymorphism.
DSH, dyschromatosis symmetrica hereditaria.
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formation of the homodimer (Cho et al, 2003), suggesting
that DSH might be caused by a dominant negative effect
(Liu et al, 2004). Further investigations will be needed to
address this issue.
In conclusion, in this study, 16 novel mutations in the
ADAR1 gene were found in 16 Japanese patients with DSH,
suggesting no founder effect in DSH patients. And this
study also established the existence of apparent differences
in the etiology of DSH, DUH, and AR. Identification of the
genes for DUH and AR is expected.
Materials and Methods
Patients All patients were Japanese and unrelated. A total of 16
patients with DSH, three patients with DUH, and three patients with
AR were included in the mutational analysis. Two, two, and one of
the patients with DSH, DUH, and AR, respectively, had no family
history of the disease and the families of the other patients turned
out to have at least one other affected individual in each family
(Table II). We screened one affected individual of each pedigree for
a mutation of the ADAR1 gene. The birthplaces of the patients
were scattered around Japan, and no high incidence area for these
three diseases were found. The patients originally consulted us for
their skin conditions. The degree of hyper- and hypopigmentation
in each patient varied from distinct to indistinct. This study was
approved by the Ethics Committee of Nagoya University Graduate
School of Medicine. This study was conducted according to the
Declaration of Helsinki Principles. Informed written consent was
obtained from each patient, or from the patient’s parents in the
case of children.
Mutation screening and detection Mutation analysis of the
ADAR1 gene was performed as previously described (Miyamura
et al, 2003). Briefly, genomic DNA was extracted from peripheral
blood leucocytes and used as a template for mutational screening
using a PCR-based SSCP/HD analysis (Spritz et al, 1992). Stand-
ard PCR amplification procedures were employed, with an an-
nealing temperature of 621C for all primers (see Table S1). Three
kinds of SSCP gels, with glycerol concentrations of 0%, 7%, and
10%, were used to elevate the sensitivity of our mutation screening
system. PCR products showing aberrant patterns on SSCP were
reamplified and sequenced directly to identify the mutation. In pa-
tients without any mutations detected by the SSCP/HD method, all
of their PCR products were directly sequenced to identify any
mutations.
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Electronic-database information Accession numbers and
URLs for data presented herein are as follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for
the cDNA of human ADAR1 [accession number NM_
001111], the genomic sequence of human ADAR1 [acces-
sion number NT_004668])
Online Mendelian Inheritance in Man (OMIM), http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM (for ADAR1,
DSH and DUH)
dbSNP Home Page, http://www.ncbi.nlm.nih.gov/
SNP/ (for ADAR1-1 [accession number rs17843863],
ADAR1-2 [accession number rs17843864], ADAR1-3 [ac-
cession number rs17843870], ADAR1-4 [accession number
rs17843865], ADAR1-5 [accession number rs17843866],
ADAR1-6 [accession number rs17843867], ADAR1-7 [ac-
cession number rs17843868], ADAR1-8 [accession number
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